rs1058164 — CYP2D6

CYP2D6 rs1058164 — The Silent Splicing Switch

Inside every liver cell, the CYP2D6 enzyme quietly processes roughly 25% of the prescription drugs on the market — from antidepressants to opioid pain relievers to antipsychotics and beta-blockers. The rs1058164 variant looks unremarkable on paper: it is a [synonymous | synonymous: the DNA change doesn't alter the amino acid sequence] change in exon 3 of CYP2D6, where valine remains valine at position 136 (Val136=). But a synonymous mutation can still be anything but silent. A landmark 2023 study demonstrated that this common variant — carried by roughly 30–45% of people worldwide — acts as a molecular switch that redirects the gene's splicing machinery, dramatically reducing how much functional CYP2D6 protein the liver makes.

The Mechanism

When a cell transcribes CYP2D6 into mRNA, a spliceosome complex must correctly join exons together and discard introns. [Exonic splicing enhancers (ESEs) | short sequences within exons that recruit splice-site-recognition proteins] normally ensure exon 3 is included in the final transcript. The rs1058164 C allele (on the plus strand; G on the coding strand) appears to disrupt or weaken one such ESE, causing the spliceosome to skip exon 3 entirely.

The resulting mRNA lacks exon 3 and encodes a truncated, non-functional protein — called [CYP2D6ΔE3 | a short isoform missing the active-site residues carried in exon 3]. Collins et al. 2023¹¹ Collins et al. 2023
Collins JM, Lester H, Shabnaz S, Wang D. A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples. Front Pharmacol, 2023 showed that liver samples from C-allele carriers produced 1.4–2.5 times more CYP2D6ΔE3 isoform than non-carriers, and had approximately 50% less full-length functional CYP2D6 protein. The effect was confirmed in transfected cell systems.

The Evidence

Collins et al. 2023²² Collins et al. 2023
Collins et al. Front Pharmacol 2023. A frequent CYP2D6 variant promotes skipping of exon 3. analyzed human liver tissue and showed that a three-SNP haplotype incorporating rs1058164, rs16947, and rs5758550 explained 59% of the variability in CYP2D6 protein levels across individuals — compared to only 36% using current standard genotyping. The rs1058164 C allele independently predicted reduced expression after accounting for the other two variants.

Lu et al. 2021³³ Lu et al. 2021
Lu J et al. Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. BMC Psychiatry, 2021 found rs1058164 among the high-frequency CYP2D6 mutation sites in a clinical cohort of schizophrenia patients, where CYP2D6 genotype correlated with risperidone plasma levels and treatment response.

Stojanović Marković et al. 2022⁴⁴ Stojanović Marković et al. 2022
From Croatian Roma to 1000 Genomes: The Story of the CYP2D6 Gene Promoter and Enhancer SNPs. J Pers Med, 2022 documented strong linkage disequilibrium between rs1058164 and CYP2D6 promoter variants across European and Asian populations, reinforcing that it is inherited as part of coherent haplotypes with functional consequences.

Hardy-Weinberg equilibrium deviations have been noted for rs1058164 in certain populations, suggesting possible selection or ascertainment effects at this locus.

Practical Implications

Because this variant reduces CYP2D6 enzyme levels rather than abolishing them entirely, the clinical impact is dose-dependent on context. Carriers of one or two C alleles are likely to metabolize CYP2D6 substrates more slowly than GG individuals, shifting them toward the intermediate metabolizer range. The practical consequences depend on which drugs are being taken:

Prodrugs like codeine and tramadol require CYP2D6 to convert them to active forms. Reduced enzyme means reduced pain relief — not a dose issue, but a conversion-efficiency issue.

Active drugs cleared by CYP2D6 (antidepressants like paroxetine and fluoxetine, antipsychotics like risperidone and aripiprazole, the beta-blocker metoprolol) may accumulate at higher-than-expected levels, increasing side-effect risk.

Tamoxifen (breast cancer treatment) requires CYP2D6 to generate its most potent active metabolite, endoxifen. Reduced enzyme means reduced endoxifen and potentially reduced efficacy.

Because rs1058164 is not yet included in standard pharmacogenomic clinical panels (which focus on star alleles defined by other variants), its contribution may be invisible to current clinical testing — adding "unexplained" variability to metabolizer predictions.

Interactions

The most important interaction is with rs16947 (CYP2D6*2) and rs5758550 (an enhancer SNP ~100 kb downstream). Collins et al. showed that a three-SNP model involving all three variants accounts for 59% of CYP2D6 protein variability. The rs5758550 G allele increases CYP2D6 expression 2-fold, partially compensating for the rs1058164 C allele's exon-skipping effect. Individuals who carry the C allele at rs1058164 but also the G allele at rs5758550 may have near-normal activity; those without the compensatory enhancer are more likely to show the reduced-protein phenotype.

The rs1058164 C allele appears to co-segregate with the rs16947 A allele on the CYP2D6*2 haplotype. This means that the full haplotype background matters substantially more than any single variant in isolation.